原发骨髓弥漫大B细胞淋巴瘤1例报告及文献复习

目的：分析1例原发骨髓弥漫大B细胞淋巴瘤（DLBCL）的诊断和治疗情况为该病的诊治提供参考。方法：结合本例患者病史及其他辅助检查结果，高度怀疑为原发骨髓淋巴瘤（PBML）。经骨髓病理检查及免疫组织化学染色确诊为DLBCL，并给予化疗。结果：本例患者符合PBML诊断标准，根据骨髓免疫组织化学染色结果将其划分至DLBCL亚型。患者接受利妥昔单抗+环磷酰胺、表柔比星、长春新碱及泼尼松（R-CHOP）方案化疗1个周期后达骨髓细胞形态学完全缓解，又行该方案化疗5个周期，现停药随访3个月仍为完全缓解。结论：骨髓病理及免疫组织化学染色对原发骨髓DLBCL具有重要的诊断价值，含利妥昔单抗的化疗方案近期疗效理想。

Primary bone marrow diffuse large B-cell lymphoma:One case report and literature review

Objective:To analyze the diagnosis and treatment of 1 case of primary bone marrow diffuse large B cell lymphoma (DLBCL),and to provide the reference for its dignosis and treatment. Methods:Combined the medical history and other auxiliary examination results, the possibility of diagnosis of primary bone marrow lymphoma (PBML)was suspected. Bone marrow biopsy and immunohistochemistry were carried out for diagnosis, and R-CHOP (rituximab, cyclophosphamide,doxorubicin,vincristine,and prednisolone) was selected as the chemotherapy scheme. Results:The diagnostic basis of the case was in accordance with the diagnostic standard of PBML.According to the results of immunohistochemical staining,it was classified as the DLBCL subtype. Then the patient received 6 cycles of R-CHOP immune chemotherapy. Complete remission of bone marrow cell morphology was gained after the first cycle of R-CHOP treatment,and the patient was treated for another five cycles and the complete remission was retained in 3 months of follow up after drug withdrawal. Conclusion:Bone marrow biospy and immunohistochemistry have the unique diagnostic values for primary bone marrow DLBCL,and the regimens containing rituximab may provide a ideal efficacy during short term observation.